Clik here to view.
サンバイオ、日本における外傷性脳損傷を対象としたフェーズ２臨床試験の被験者組み入れ開始のお知らせ
東京 （ビジネスワイヤ） — サンバイオ株式会社（本社:東京都中央区、代表取締役社長：森...
View ArticleClik here to view.
First Patient is Enrolled in Global STEMTRA Trial for Traumatic Brain Injury...
MOUNTAIN VIEW, Calif. & TOKYO SanBio Co., Ltd., a scientific leader in regenerative medicine for neurological disorders, today announced that the first patient in Japan was enrolled in the...
View ArticleClik here to view.
Astellas Reports First Half FY2016 Financial Results, Revises Fiscal Year...
TOKYO Astellas Pharma Inc. (TOKYO:4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for the first six months of fiscal year 2016 ending March 31, 2017...
View ArticleClik here to view.
Takeda Reports First Half FY2016 Results and Raises Full Year Profit Guidance
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first half results led by Growth Drivers Underlying Revenue grew +7.4%, led by a +15.3% increase of Takeda’s Growth...
View ArticleClik here to view.
2016年度上期（4‐9月期）の連結業績について当期利益およびEPSの年間予想、実質的なコア・アーニングスのマネジメントガイダンスを上方修正
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： タケダ成長ドライバーが力強い上期実績を牽引 売上収益の実質的な成長は、タケダ成長ドライバー（消化器系疾患領域、オンコロジー、中枢神経系疾患領域、新興国事業）の＋15.3％の伸長により、対前年同期＋7.4％を達成。財務ベースでは、為替影響（△8.6ポイント）や事業等の売却影響（△4.7ポイント）により対前年同期△5.9％...
View ArticleClik here to view.
面对事实：卒中是可以治疗的
印度海得拉巴 (美国商业资讯) — 世界上每2秒钟就有人发生卒中。卒中是全球第一致残原因和和第二死因。 正确的卒中医护能够挽救生命，但全球并非每个人都能获得平等的挽救生命的治疗。 今天是世界卒中日（2016年10月29日星期六），世界卒中组织(WSO)呼吁全球行动起来减少卒中治疗中的不平等，以帮助挽救数百万生命。 在印度海得拉巴召开的世界卒中大会上，WSO主席Stephen...
View ArticleClik here to view.
事実を直視する：脳卒中は治療可能
印ハイデラバード （ビジネスワイヤ） — 世界中では2秒に1人のペースで誰かが脳卒中を起こしています。脳卒中は世界で障害の主因の第1位、死亡の主因の第2位を占めています。 脳卒中の正しい治療は命を救うことができますが、世界では命を救う治療へのアクセスは誰もが同じというわけではありません。...
View ArticleClik here to view.
World-Leading Experts Collaborate at Cochlear’s Global Research Symposium
SYDNEY There are 360 million people living with disabling hearing loss worldwide and this figure is set to increase significantly to 1.2 billion by 2050.,12 To prepare for the expanding needs of...
View ArticleClik here to view.
Manchester United and Mlily in Global Partnership
MANCHESTER, England Manchester United (NYSE:MANU) is today announcing a global partnership with Mlily (SH.603313). The agreement heralds United’s first ever Official Mattress and Pillow Partner. The...
View ArticleClik here to view.
武田公布2016财年上半年业绩并提高全年利润指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(TOKYO:4502)： 强劲的上半年业绩得益于增长引擎 得益于武田增长引擎（胃肠药、肿瘤药、CNS和新兴市场）+15.3%的增长，基础营收增长+7.4%。 由于不利的汇率影响（-8.6个百分点）和剥离影响（-4.7个百分点），报告的营收下降5.9%。...
View ArticleClik here to view.
Takeda: CSR Programs Focusing on Maternal and Child Health
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that the company will implement three CSR programs focusing on solutions to maternal and child healthcare problems in...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
Takeda Donates 1 Billion Yen as an Exclusive Partner to the United Nations...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that Takeda will exclusively support “Global Measles Vaccination for Children” by the United Nations Foundation’s...
View ArticleClik here to view.
Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China
NEW YORK Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its pneumococcal 13-valent conjugate vaccine, Prevenar 13®, in...
View ArticleClik here to view.
Cindat and Union Life to Invest in a Welltower U.S. Health Care Real Estate...
TOLEDO, OHIO & BEIJING Welltower Inc. (NYSE:HCN), Cindat Capital Management Limited (“Cindat”) and Union Life Insurance Co. Ltd (“Union Life”) announced today that they have entered into a...
View ArticleClik here to view.
Takeda to Present Broad Range of Clinical Data During 58th American Society...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 16 company-sponsored abstracts at the 58th American Society of...
View ArticleClik here to view.
武田作为“全球儿童麻疹疫苗接种”项目独家合作伙伴向联合国基金会捐款10亿日元
日本大阪 (美国商业资讯) –武田药品工业株式会社(TOKYO:4502)今天宣布，武田将独家支持联合国基金会Shot@Life运动开展的“全球儿童接种麻疹疫苗”。该倡议的目标是在10年期间为非洲、亚洲和拉丁美洲近40个发展中国家的至少540万名儿童提供麻疹疫苗接种。本公司已向联合国基金会捐款10亿日元，以落实该项目。...
View ArticleClik here to view.
武田：专注于妇幼卫生的CSR项目
日本大阪 (美国商业资讯) — 武田药品工业株式会社(TOKYO:4502)今天宣布，公司将落实3个专注于非洲和亚洲妇幼医疗保健问题解决方案的企业社会责任(CSR)项目。这些项目将从中长期角度解决妇幼卫生的重大问题，并与下列拥有可靠追踪记录的国际性非政府组织(NGO)合作落实：World Vision Japan、Save the Children Japan和Plan...
View ArticleClik here to view.
Boyalife Announces Recent Changes to Management and the Board of Directors of...
WUXI, China Boyalife Investment Inc. and Boyalife (Hong Kong) Limited (collectively, “Boyalife”), as the majority shareholders of Cesca Therapeutics Inc. (NASDAQ: KOOL) (the “Company), an autologous...
View Article